Meropenem Hikma (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, which are essential for the cross‑linking of peptidoglycan strands. This inhibition disrupts cell wall integrity, causing osmotic lysis and rapid bactericidal activity against a wide range of Gram‑positive, Gram‑negative, and anaerobic organisms.

The dosage of Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals set the appropriate dose and infusion schedule for each individual case.

Safety data for meropenet in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each situation carefully and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems but offers a slightly lower risk of seizure activity compared with imipenem and a more convenient dosing interval than ertapenem for certain infections. Choice among carbapenems depends on pathogen susceptibility, infection site, and patient‑specific factors.

Meropenem Hikma should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Once reconstituted, follow the manufacturer’s guidance for stability and use within the recommended time frame.

Meropenem Hikma is supplied as a sterile powder for intravenous infusion. The powder is reconstituted with the appropriate diluent and administered over 15‑30 minutes, depending on the clinical protocol. Infusion rates and duration are determined by the treating physician.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, seizures (particularly in patients with CNS disorders or renal impairment), and acute renal dysfunction. Prompt recognition and management of these events are essential.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics should avoid this drug. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving concomitant valproic acid therapy.